Document is current
Any future updates will be listed below
-
Authors
Cruz-Rodriguez, Nataly
Tang, Hua https://orcid.org/0000-0002-3342-8789
Bateman, Benjamin https://orcid.org/0009-0007-1511-5862
Tang, Weiping https://orcid.org/0000-0002-0039-3196
Deininger, Michael https://orcid.org/0000-0002-2987-1331
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA257602, R01CA268496, R01CA254354)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | National Institutes of Health (R35GM148266, R01CA284689)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 1 May 2024
Revised: 19 June 2024
Accepted: 24 July 2024
First Online: 4 August 2024
Competing interests
: Michael Deininger is a consultant for Blueprint Medicines, Novartis, CTIBioPharma, Incyte, Dava Oncology, Pfizer, and Cogent. Weiping Tang is a cofounder and shareholder of Chimergen Therapeutics Inc.
